PharmNXT Biotech
For decades, India has earned global recognition as the "Pharmacy of the World," supplying affordable generic medicines and vaccines to millions across the globe. Today, however, the country's pharmaceutical industry is undergoing a significant transformation. As healthcare systems increasingly adopt biologics, biosimilars, cell therapies, and precision medicine, India is preparing for a new manufacturing era-one that demands far greater technological sophistication than conventional pharmaceutical production.
At the heart of this shift is a growing need for advanced bioprocessing infrastructure, an area where Pune-based PharmNXT Biotech is building its presence.
Founded in 2017 by Sachin Joshi and Ankush, PharmNXT Biotech specializes in the design and manufacturing of single-use bioprocessing systems that support the production of biologics, vaccines, and other advanced therapies. While biologics are expected to account for a significant share of the global pharmaceutical market-projected to exceed USD 600 billion by 2030-the infrastructure required to manufacture these therapies remains highly specialized and quality sensitive.
Unlike traditional pharmaceutical manufacturing, biologics production relies on living cells and requires tightly controlled environments, sterile fluid management systems, contamination-free processing, and rigorous quality controls. As pharmaceutical companies expand their biologics pipelines, demand for advanced manufacturing systems is rising rapidly.
"India's pharmaceutical ecosystem is entering a new phase where manufacturing capability will increasingly be defined not just by scale, but by the ability to support complex biologics production through advanced bioprocessing infrastructure, flexible manufacturing systems, and globally compliant quality standards," said Sachin Joshi, Founder, PharmNXT.
Enabling the Next Generation of Drug Manufacturing
PharmNXT operates from its clean-room manufacturing facility in Pune, producing a range of single-use bioprocessing solutions used across biologics and vaccine manufacturing environments. Its portfolio includes bioprocess bags, filtration systems, mixing systems, tubing assemblies, fluid management systems, and sterile containment solutions.
These systems play a critical role in modern pharmaceutical manufacturing. As biologics become more complex and production cycles shorten, manufacturers increasingly require flexible, contamination-controlled systems that can be deployed quickly while maintaining strict compliance standards.
The industry's growing preference for single-use technologies reflects this need. Such systems help reduce contamination risks, improve operational efficiency, eliminate cleaning validation requirements, and support faster facility turnaround times. Globally, the single-use bioprocessing market is projected to surpass USD 30 billion in the coming years, driven by increasing adoption across biologics manufacturing facilities.
Riding India's Biologics Growth Story
India's ambitions in biotechnology continue to accelerate. The country's bioeconomy is expected to reach USD 300 billion by 2030, supported by rising investments in biosimilars, vaccine development, monoclonal antibodies, and advanced therapies.
India already contributes nearly 60 percent of global vaccine production and is steadily strengthening its capabilities in biologics and complex therapeutics. Industry forums such as BioAsia have increasingly highlighted the importance of developing domestic manufacturing capabilities that extend beyond drug formulation into the infrastructure and technologies that enable advanced drug production.
For companies like PharmNXT, this presents a strategic opportunity.
Rather than competing solely on cost, Indian manufacturers are increasingly being challenged to deliver products that meet stringent global standards for quality, traceability, consistency, and regulatory compliance. This is particularly critical in biologics manufacturing, where even minor variations can significantly impact product safety and efficacy.
Building for the Future of Healthcare
As healthcare continues to evolve toward personalized medicine, cell and gene therapies, and biosimilars, manufacturing requirements will become even more demanding. Facilities will need systems that are scalable, modular, and capable of supporting smaller, more targeted production batches while maintaining uncompromising quality standards.
"The future of biologics manufacturing will be driven by precision, flexibility, and compliance. As cell therapies, biosimilars, and personalised medicine continue to grow, manufacturers will require scalable systems that can support faster production cycles while maintaining high standards of sterility, consistency, and traceability," said Ankush, Founder, PharmNXT.
With India's pharmaceutical sector moving beyond its traditional strengths in generics and vaccines, companies that can provide the enabling infrastructure for biologics manufacturing are expected to play an increasingly important role in global healthcare supply chains.
As the next chapter of pharmaceutical innovation unfolds, PharmNXT is positioning itself not merely as a supplier of manufacturing components, but as a contributor to the ecosystem that will power the future of biologics manufacturing in India and beyond.
